Royalty Pharma
RPRX
RPRX
362 hedge funds and large institutions have $10B invested in Royalty Pharma in 2023 Q4 according to their latest regulatory filings, with 79 funds opening new positions, 146 increasing their positions, 110 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
23% more capital invested
Capital invested by funds: $8.16B → $10B (+$1.88B)
16% more funds holding
Funds holding: 312 → 362 (+50)
13.28% more ownership
Funds ownership: 66.7% → 79.98% (+13%)
Holders
362
Holding in Top 10
8
Calls
$25.5M
Puts
$17.5M
Top Buyers
| 1 | +$1.25B | |
| 2 | +$72.4M | |
| 3 | +$59M | |
| 4 |
Swedbank
Stockholm,
Sweden
|
+$42.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$35.8M |
Top Sellers
| 1 | -$68.8M | |
| 2 | -$63.8M | |
| 3 | -$40.4M | |
| 4 |
Goldman Sachs
New York
|
-$37.7M |
| 5 |
RCM
Rokos Capital Management
London,
United Kingdom
|
-$29.6M |